louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01216267: Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
Official title: Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neuroendocrine Carcinoma (Carcinoid)
Keywords: chromogranin A
neuroendocrine
carcinoid
Proton Pump Inhibitor
Lead sponsor: University of Western Ontario, Canada
Sponsor class: OTHER
First posted: 2010-10-07
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors.

Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.

Detailed description: Patient group: patients with neuroendocrine tumors (active or inactive) Healthy volunteers

Eligibility criteria: Patients:

Inclusion Criteria:

* having neuro-endocrine disease

Exclusion Criteria:

* age below 18 or above 70 years
* prostate cancer
* kidney failure (estimated GF \< 30 mL/Min)
* heart failure
* chronic atrophic gastritis
* pregnancy

Healthy subjects:

Inclusion Criteria:

* healthy

Exclusion Criteria:

* age below 18 or above 70 years
* taking any chronic medication (except OCP)
* prostate cancer
* kidney failure (estimated GFR \< 30 mL/min)
* heart failure
* pheochromocytoma
* islet cell tumors
* medullary thyroid cancer
* essential hypertension
* neurofibromatosis
* use of proton pump inhibitors
* chronic atrophic gastritis
* pregnancy

Primary outcomes:
measure: chromogranin A concentration serum
timeFrame: single time
Secondary outcomes:
measure: Effect of PPI on chromogranin A concentration
timeFrame: 2 weeks
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Sciences Center and St. Joseph's Health Care
state: Ontario
Study officials:
affiliation: Western University, Canada
name: Stan Van Uum, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05187767: Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs
Official title: Impact of Circulating Tumor DNA on Early Cancer Detection and Evaluation of STAS in Patients With Ground Glass Opacities
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Cancer
Spreading of Tumor
Circulating Tumor Cell
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2022-01-12
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with radiological finding of pulmonary ground glass opacity of unknown origin

Brief summary: The aim of the study is the early and non-invasive diagnosis of lung cancer in patients with pulmonary ground glass opacity. In particular, objective of the study is to evaluate the presence or absence of circulating tumor DNA (ctDNA) on the peripheral blood of patients with evidence of ground glass opacity(GGO) at CT scan and to evaluate the role that this can play in the diagnostic / therapeutic process. The ctDNA evaluation will be performed at the first radiological finding and subsequently correlated with the malignancy of the lesion based on the radiological / histological criteria regularly used in international protocols.

Secondary objective is the correlation, in patients with malignant GGO undergoing surgical treatment, of the ctDNA presence and tumor spread through the air spaces (STAS), and its correlation with local relapses.


Eligibility criteria: Inclusion Criteria:

* age\> 18 years
* radiological finding of pulmonary ground glass opacity
* absence of solid or haematological tumor

Exclusion Criteria:

* radio / chemotherapy treatment for at least 6 months
* patient unable to understand and express his consent to the study

Primary outcomes:
measure: Quantification of cf DNA
timeFrame: through study completion, an average of 2 year
measure: Presence of ct DNA
timeFrame: through study completion, an average of 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Thoracic Surgery Unit, Sapienza University of Rome
Study officials:
affiliation: University of Roma La Sapienza
name: Marco Anile, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03021967: Perceptions of Health Professionals Confronted With Palliative Situations
Official title: Preliminary Study: Perceptions of Doctors and Caregivers Confronted With Adult Patients in Advanced or Terminal Stage of a Severe, Progressive and Incurable Pathology in the Services of the Hospitals University of Strasbourg Including Beds Identified Palliative Care
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Incurable Pathologies
Keywords: incurable pathologies
palliative care
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2017-01-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitals, doctors and caregivers, who take care of increasingly heavy patients,

Brief summary: Hospitals, doctors and caregivers, who take care of increasingly heavy patients, are faced with ever more complex situations, particularly in the case of severe, progressive, and incurable pathologies.

Thanks to their willingness and expertise, these care providers try to guarantee the continuity and quality of care for both patients and patients in a palliative situation. Nevertheless, these same actors testify to the complexity they encounter in the care of patients in advanced or terminal stages, especially since the concept of "palliative care", which was often erroneously reduced during the Any end of life and therefore death, remains a source of questions, contradictions, even resistances.

In this context, how do physicians and caregivers appropriate palliative care? How do they react to the complexity and intensity of certain situations? Do they have specific expectations of help or support in the face of certain difficulties? Are there actions to be carried out and developed to make the aid given to these actors of the palliative approach more efficient?

These are the topics that the HUS palliative care service proposes to explore through a study of physicians and caregivers working in HUS services for adult patients with LISP.


Eligibility criteria: Inclusion Criteria:

* Major hospitals, doctors and caregivers, who take care of increasingly heavy patients

Exclusion Criteria:

* Patient under 18 years

Primary outcomes:
measure: Questionnaire
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service Soins Palliatifs
Study officials:
affiliation: University Hospital, Strasbourg, France
name: Laurent CALVEL, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06010667: A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Official title: A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Epithelial Ovarian Cancer
Lead sponsor: Hebei Medical University Fourth Hospital
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: epithelial ovarian cancer (EOC), fallopian tube cancer, primary peritoneal cancer

Brief summary: The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer.


Eligibility criteria: Inclusion Criteria:

* Age 18-70 years Histologically or pathologically confirmed epithelial ovarian cancer (EOC), fallopian tube cancer, primary peritoneal cancer Patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer following platinum-based chemotherapy measurable lesions (according to RECIST 1.1 criteria, non-lymph node lesions CT scan long diameter ≥ 10 mm, lymph node lesions CT scan short diameter ≥ 15 mm) ECOG PS score: 0 - 1;

Exclusion Criteria:

* Subject has prior or concurrent other malignancy Prior treatment with other PD-L1/PD-L1 inhibitors cannot be enrolled; Subject has known previous hypersensitivity to macromolecular protein preparations or applied drug components

Primary outcomes:
measure: overall response rate;ORR
timeFrame: 2years
Secondary outcomes:
Other outcomes:
Locations:
city: Shijiazhuang
country: China
facility: Hebei
state: Hebei
Study officials:
References:
Clinical trial NCT01133067: Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients
Official title: A Prospective Study of Telephonic Contact and Subsequent Physical Follow up of Radically Treated Lung Cancer Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Keywords: lung cancer
followup
physical follow up
telephonic followup
Lead sponsor: Tata Memorial Hospital
Sponsor class: OTHER_GOV
First posted: 2010-05-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All curative lung cancer patients after there intial primary treatment who have already been given scheduled appointment shall be called telephonically every 3 months. A set of questions shall be asked to the patient in his /her vernacular during the telephonic interview.After the telephonic interview, the patients shall then report to the cancer care specialist at the Hospital for the due follow up visit.

Brief summary: Does the routine clinical practice of follow up after primary treatment in lung cancer patients has any utility.

Detailed description: Patients of cancer, after their primary treatment are subsequently called for follow up visits to assess the disease status. This has two important implications from the point of view of resource management. One, patients often have to travel long distances to report to the hospital and have to take care of other logistics such as their accommodation, local travel and food. Further often the patient travels with 1-2 attendants which adds to the logistic burden. Also, these patients of follow up also contribute to the load on existing hospital services. Many authors have speculated that follow-up visits generate anxiety about possible disease recurrence. On the other hand, many others have suggested that although there may be a transient increase in anxiety, patients are ultimately reassured by this practice. Hence, there is no firm evidence for the practice and the need for follow up in oncology care.

Eligibility criteria: Inclusion Criteria:

1. All patients of lung cancer treated with a radical aim (e.g surgery, Chemoradiation, surgery followed by adjuvant treatment or any other combination)
2. Patients should have completed radical /adjuvant treatment, if any
3. Patients of both SCLC and NSCLC
4. Patients with at least two telephone numbers (landline/mobile/both)
5. Patients willing to participate

Exclusion Criteria:

1. All patients for palliative intention
2. Patients with less than two contact telephone numbers -

Primary outcomes:
measure: Concurrence Between the Telephonic Interview and the Physician Assessment
timeFrame: 2 years
Secondary outcomes:
measure: Cost Analysis
timeFrame: 2 years
Other outcomes:
Locations:
city: Mumbai
country: India
facility: Tata Memorial Hospital
state: MS
Study officials:
affiliation: Tata Memorial Hospital
name: JP AGARWAL, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03720067: Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
Official title: Propranolol, Carvedilol and Rosuvastatin in the Prevention of Recurrent Variceal Haemorrhage in Patients With Cirrhotic Portal Hypertension
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Cirrhosis
Portal Hypertension
Variceal Hemorrhage
Lead sponsor: Universidade Federal do Rio de Janeiro
Sponsor class: OTHER
First posted: 2018-10-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with hepatic cirrhosis and previous variceal bleeding will be randomly assigned to use propranolol or carvedilol. After 8 weeks, rosuvastatin or placebo will be blindly added to nonresponders (HVPG measurement \> 12mmHg) for another 8 weeks and hemodynamic response will be assessed again.

Surrogate serum markers of portal hypertension will be evaluated and correlated to HVPG values and to its variations.


Eligibility criteria: Inclusion Criteria:

* Hepatic cirrhosis of any etiology
* Previous variceal bleeding
* Endoscopic variceal eradication at least 2 weeks before

Exclusion Criteria:

* Beta blocker or statin contraindications
* Model for End-Stage Liver Disease (MELD) score \> 25
* Child-Pugh score \> 13
* HVPG ≤ 12 mmHg
* Creatinine clearance \< 50 mL/min
* Refractory ascites
* Hepatic encephalopathy stages 3 or 4
* Alcohol use in the last 6 months
* Hepatitis C treatment in the last 6 months
* Changing or initiating a new hepatitis B treatment in the last 6 months
* Malignant neoplasms from any origin except basal cell carcinoma
* HIV infection
* Pregnancy
* Anticoagulation
* Recent or complete portal vein thrombosis

Primary outcomes:
measure: Acute hemodynamic response
timeFrame: Two hours after a load dose of carvedilol or propranolol
measure: Full hemodynamic response to beta blockers
timeFrame: Eight weeks of carvedilol or propranolol
measure: Full hemodynamic response to beta blockers plus rosuvastatin or placebo
timeFrame: Eight weeks of beta blockers plus rosuvastatin or placebo
Secondary outcomes:
measure: Sufficient hemodynamic response to beta blockers plus rosuvastatin or placebo
timeFrame: Eight weeks of beta blockers plus rosuvastatin or placebo
measure: Partial hemodynamic response to beta blockers plus rosuvastatin or placebo
timeFrame: Eight weeks of beta blockers plus rosuvastatin or placebo
Other outcomes:
Locations:
city: Rio de Janeiro
country: Brazil
facility: Universidade Federal do Rio de Janeiro
Study officials:
References:
Clinical trial NCT05143567: Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications
Official title: Comprehensive Assessment of the Hemostasis and Inflammation in Patients With Venous and Arterial Thrombotic Complications in Treatment of New Coronaviral Infection (COVID-19)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Venous Thromboembolism
covid19
Thrombosis
Keywords: venous thromboembolism
VTE
thrombotic events
coronavirus
COVID-19
hemostasis
platelet function
Lead sponsor: Ryazan State Medical University
Sponsor class: OTHER
First posted: 2021-12-03
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open-label cohort longitudinal study
Primary purpose: OTHER

Brief summary: The study is aimed at assessing the role of the activity of high-risk markers of thrombotic events (MCP-1, MIP1α, IP-10, phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with COVID -19.

Detailed description: The study is aimed at assessing the role of the activity of high-risk markers for thrombotic events (monocytic chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1α (MIP1α), interferon-induced gamma protein-10 (IP-10), platelet apoptosis markers (phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with COVID -19.

The study will include 150 patients of similar age, gender, and ethnicity, and they will be divided into three groups: Group I: 50 patients with confirmed coronavirus infection without thrombotic complications; Group II: 50 patients with confirmed coronavirus infection with thrombotic complications confirmed by ultrasonography without the use of pharmacomechanical prophylaxis of VTE; Group III: 50 patients with confirmed coronavirus infection with ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities using pharmacomechanical prophylaxis of VTE

Eligibility criteria: Inclusion Criteria:

* men or women over 18 years of age with a new coronavirus infection, confirmed by polymerase chain reaction (PCR) studies and chest CT.

Exclusion Criteria:

* men or women under 18 years of age; active cancer or a remission period of less than 5 years; decompensated somatic pathology; pregnancy or breastfeeding in women.

Primary outcomes:
measure: mortality
timeFrame: one year
measure: venous thrombosis or pulmonary embolism
timeFrame: one year
measure: arterial thrombosis
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Ryazan'
country: Russian Federation
facility: Ryazan State Medical University
Study officials:
affiliation: Ryazan State Medical University
name: Igor Suchkov, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT02297867: Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis
Official title: Adipose-Derived Stem Cells (ADSCs) Injections for Liver Cirrhosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Liver Cirrhosis
Lead sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-11-21
Enrollment: 6
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.

Detailed description: One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.

Eligibility criteria: Inclusion Criteria:

1. Liver cirrhosis investigators with age 20 to 80 years (both inclusive).
2. Investigators without Mandatory Communicable Disease (HBV, HCV, HIV, syphilis)
3. Investigators without rare disorder
4. Coagulation normalities
5. Investigators without autoimmune disorder
6. Investigators without Acquired Immune Deficiency Syndrome
7. Investigators without cancer
8. Investigators BMI \> 15

Exclusion Criteria:

1. Pregnant women
2. Investigators with acute stroke in one month and unconsciousness
3. Investigators with acute myocardial infarction or acute heart failure
4. Investigators with serious liver dysfunction and coagulation dysfunction and ascites mild higher
5. Investigators with acute respiratory failure or pneumonia
6. Kidney Failure: BUN \> 50
7. Anemia: Hematocrit \< 25
8. Investigators diagnosed with liver cancer or liver metastatic carcinoma
9. Investigators with liver abscess
10. Investigators with acute Hepatitis
11. Investigators with acute infective
12. Liver cirrhosis patients with HBV or HCV
13. Investigators diagnosed with carcinoma and receiving treatment
14. Investigators with Schizophrenia or melancholia
15. Investigators received serious surgical operations in 3 months
16. Investigators unable to control hypertension (SBP \> 180 mmHg, DBP \> 110 mmHg) or diabetes (AC sugar \> 200 mg/dl)
17. Others can't fit into the trial evaluate by investigator

Primary outcomes:
measure: MELD
timeFrame: 1-6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Beigang Hospital
state: Beigang
city: Hsinchu
country: Taiwan
facility: Gwo Xi Stem Cell Applied Technology Co., Ltd.
Study officials:
affiliation: China Medical University Beigang Hospital
name: CMU B Hospital
role: STUDY_DIRECTOR
References:
citation: Harn HJ, Lin SZ, Hung SH, Subeq YM, Li YS, Syu WS, Ding DC, Lee RP, Hsieh DK, Lin PC, Chiou TW. Adipose-derived stem cells can abrogate chemical-induced liver fibrosis and facilitate recovery of liver function. Cell Transplant. 2012;21(12):2753-64. doi: 10.3727/096368912X652959. Epub 2012 Jul 5.
Clinical trial NCT06775067: Incremental Dialysis Decision Model Based on Expert-Guided Machine Learning
Official title: Machine Learning Based on Expert Knowledge to Build and Validate a Decision Model for Incremental Dialysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: End-stage Renal Disease
Keywords: Machine Learning
Expert Knowledge
Interpretability
Incremental Hemodialysis
Decision Model
Lead sponsor: Huashan Hospital
Sponsor class: OTHER
First posted: 2025-01-14
Enrollment: 175
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hemodialysis patients with residual renal function admitted to dialysis centers

Brief summary: This observational prospective study combined clinical expert knowledge with machine learning to develop and validate a predictive model for incremental hemodialysis decision-making. The aim of the predictive model is to assist clinicians in developing individualized incremental dialysis treatment plans to optimize patient outcomes.

Detailed description: By collecting patients' clinical and biochemical parameters and combining them with experts' judgments of dialysis timing and frequency, the model can dynamically assess patients' risk of needing to increase the frequency of dialysis, thus assisting physicians in formulating individualized incremental dialysis regimens to optimize dialysis outcomes and improve patients' prognosis.

Eligibility criteria: Inclusion Criteria:

1. New hemodialysis patients (Apr 2010-Jun 2024), started within 3 months, including transfers.
2. Age ≥18, stable hemodialysis \>6 months.

Exclusion Criteria:

1. Incomplete/unreliable data.
2. Twice-weekly palliative dialysis.
3. No baseline urine output or ≤200 mL/24h.
4. Liver disease, heart failure, or severe comorbidities.

Primary outcomes:
measure: Number (Proportion) of Participants Who Experience an Incremental Dialysis Event, Assessed Monthly
timeFrame: Baseline and monthly visits from enrollment until incremental dialysis event, death, transfer, or up to 5 years (whichever occurs first)
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Huashan hospital, Fudan university
state: Shanghai
Study officials:
affiliation: Huashan Hospital
name: Jing Chen
role: PRINCIPAL_INVESTIGATOR
References: